(CercleFinance.com) – Bristol Myers Squibb announced that Opdivo (nivolumab) has been approved by the United States Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients aged 12 years and older with a completely resected stage IIB or IIC melanoma.
Opdivo is the only -1 inhibitor indicated as adjuvant therapy in eligible patients with stage IIB, IIC, III melanoma1 as well as completely resected stage IV melanoma 1.
In the trial, Opdivo reduced the risk of recurrence, new primary melanoma, or death in patients with completely resected stage IIB or IIC melanoma by 58% compared to placebo.
‘Within five years of diagnosis, one-third of patients with surgically resected IIB melanoma and nearly half of patients with surgically resected IIC melanoma have their cancer return, highlighting the need for treatment options. additional treatment that can help reduce the risk of cancer coming back,’ said John M. Kirkwood, MD, professor emeritus of medicine at the University of Pittsburgh School of Medicine and co-director of the Hillman Cancer Center’s Melanoma Center. of UPMC.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
